Second, in a randomized controlled trial, individual carrying FLAP or LTA4 hydrolase haplotypes associated with an increased risk of myocardial infarction shown reduced C-reactive protein levels when treated with the FLAP antagonist DG-031 [80]. This evidence concerns the gene ALOX5AP and myocardial infarction.